SCHEMBL851112

SCHEMBL851112

C=C(C)C(=O)NC(CC)[Si](O[SiH2]c1cccc(C)c1C)(O[SiH2]c1cccc(C)c1C)O[SiH2]c1cccc(C)c1C

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
NLRP3 Q96P20 1/20 0.30
THRB P10828 1/20 0.30
MAPT P10636 1/20 0.30
RAB9A P51151 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1517424 0.85 ACACB (0.34) GAAHTTLMNAALDH1A1HPGD
SCHEMBL851353 0.76 HTT (0.32) HTTLMNA
SCHEMBL135381 0.72 TGFBR1 (0.41) ALDH1A1
SCHEMBL850359 0.71 TGFBR1 (0.35)
SCHEMBL850358 0.69 TGFBR1 (0.33)
SCHEMBL7184008 0.69 ALDH1A1 (0.35) GAALMNAALDH1A1TDP1HPGD
SCHEMBL851111 0.68 KDM4E (0.36) GAALMNAALDH1A1HPGDKMT2A
SCHEMBL79937 0.68 TGFBR1 (0.40) THRB
SCHEMBL393260 0.67 POLB (0.38) GAAHTTALDH1A1TDP1CYP3A4
SCHEMBL308679 0.67 TGFBR1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432808-B1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2015-10-21 EP claimed
US-9097839-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2015-08-04 US claimed
US-8383744-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2013-02-26 US claimed
US-20120172478-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2012-07-05 US claimed
US-8163206-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2012-04-24 US claimed
EP-2432808-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS Novartis AG (CH) 2012-03-28 EP claimed
EP-2374031-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES Novartis AG (CH) 2011-10-12 EP claimed
WO-2010133680-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS NOVARTIS AG (CH) 2010-11-25 WO claimed
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS ALCON INC. (CH) 2010-11-25 US claimed
US-20100258961-A1 Method for making silicone hydrogel contact lenses ALCON INC. (CH) 2010-10-14 US claimed
WO-2010071691-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES NOVARTIS AG (CH) 2010-06-24 WO claimed
EP-3486711-A1 LENS-FORMING MATERIALS COMPRISING PREPOLYMERS SUITABLE FOR MAKING ULTRA-VIOLET ABSORBING CONTACT LENSES Novartis AG (CH) 2019-05-22 EP disclosed
US-9097839-B2 Method for making silicone hydrogel contact lenses NOVARTIS AG (CH) 2015-08-04 US disclosed
US-9066981-B2 Actinically-crosslinkable siloxane-containing copolymers NOVARTIS AG (CH) 2015-06-30 US disclosed
US-20140100291-A1 Actinically-Crosslinkable Siloxane-Containing Copolymers NOVARTIS AG (CH) 2014-04-10 US disclosed
EP-0675910-B1 NOVEL MACROMONOMERS BAUSCH & LOMB (US) 1997-09-17 EP disclosed
US-5563184-A CONTACT LENSES BAUSCH & LOMB INCORPORATED (US) 1996-10-08 US disclosed
EP-0675910-A1 NOVEL MACROMONOMERS. BAUSCH & LOMB (US) 1995-10-11 EP disclosed
US-5387663-A Polymerized with hydrophilic or hydrophobic monomers for biomedical devices, contact lenses BAUSCH & LOMB INCORPORATED (US) 1995-02-07 US disclosed
WO-1994015980-A1 NOVEL MACROMONOMERS BAUSCH & LOMB INCORPORATED (US) 1994-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100296049-A1 ACTINICALLY-CROSSLINKABLE SILOXANE-CONTAINING COPOLYMERS VCL, MACF1, CFL1 GAA 3338/4885HTT 958/4885LMNA 1029/4885
US-20140100291-A1 Actinically-Crosslinkable Siloxane-Containing Copolymers ATRIP, ATR, MACF1 GAA 4052/4885HTT 468/4885LMNA 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.